PARIS — Pierre Fabre Laboratoires has taken a minority stake in MiYé, the French skincare and dietary supplements brand specializing in women’s hormonal balance and well-being — a burgeoning category in the wonder industry today.

Financial terms of MiYé’s first funding round, with Pierre Fabre the only investor, weren’t disclosed. But the businesses jointly said in a press release that the investment will help the brand speed up its development, due to Pierre Fabre labs’ know-how in medicine and the pharmacy market.

Within the near term, MiYé is readying to develop an awareness-raising and personalized support program involving online consultations with naturopaths and micronutritionists.

MiYé was cofounded in 2020 by Caroline de Blignières and Anna Oualid, with the backing of a scientific community specialized within the endocrine system. The brand, whose name means “good friend” in Provençal, was created to assist women live higher with hormone fluctuations throughout their lives.

MiYé has a variety of 13 products, including five dietary supplements and eight dermocosmetics, which deal with performance, naturalness, safety and ease of use.

“Pierre Fabre Laboratories’ acquisition of a stake in MiYé two years after our launch is a improbable endorsement,” de Blignières said in a press release. “It’s a useful opportunity to strengthen our R&D resources, in order that we are able to promote the democratization of girls’s hormonal health and work together to redefine the foundations of a recent ecology for the feminine body — one which is holistic, transgenerational and, above all, safer.”

“Once we launched MiYé, we set ourselves the ambitious goal of constructing a medical topic easier to grasp for most people by utilizing cosmetics concepts in tune with women’s every day routines, via premium, multichannel distribution,” Oualid said. “Who higher to support us today than Pierre Fabre, with its longstanding commitment to women’s health?”

Pierre Fabre Laboratories, which was created in 1962, has an investment subsidiary called Pierre Fabre Invest. Through that, the group acquires stakes in what it considers fast-growing start-ups with a positioning that enhances its own dermocosmetics brands.

Pierre Fabre Invest became the bulk stakeholder in Ladrôme Laboratoire, which makes a speciality of organic skincare and cosmetics, in 2021. Additionally it is the one shareholder of Même Cosmetics, which makes wellness treatments for individuals with cancer.

“Hormonal balance is a serious stake that dermocosmetics shall address. With MiYé, Caroline de Blignières and Anna Oualid have found a strategy to support women from puberty to menopause,” said Frédéric Ennabli, chief executive officer of Pierre Fabre Dermo-Cosmétique. “They’ve created a brand with a powerful territory, with specialized and differentiating products which might be now esteemed by consumers, resembling the Completely satisfied Cycles Serum.

“By partnering with MiYé, we’re committed to providing our medical and dermatological expertise to develop the perfect possible responses to deal with all skins affected by hormonal variations,” he continued. “We’re thus continuing Pierre Fabre Laboratories’ longstanding commitment to supporting women’s health by enabling pharmacists to accompany them in the perfect possible way, whether through our democosmetics or our medicines, which have pioneered the treatment of iron deficiency anemia, a quite common condition while pregnant, and now due to this strategic partnership.”